Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Bempedoic acid [738606-46-7]

Bempedoic acid [738606-46-7]

Imprimer Imprimer
Identifiez-vous

Référence orb1303985-10mg

Conditionnement : 10mg

Marque : Biorbyt

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Bempedoic acid

SKU: orb1303985

Description

Bempedoic acid (ETC1002) is an oral, once-daily small molecule that lowers LDL-C via hepatic uptake mechanisms distinct from statins, aiming to reduce associated side effects. It is utilized in cardiovascular disease research, with studies demonstrating its efficacy in both in vitro assays and in vivo models of hyperlipidemia.

Research Area

Epigenetics & Chromatin, Metabolism Research, Pharmacology & Drug Discovery, Signal Transduction

Images & Validation

−
Bempedoic acid

Key Properties

−
CAS Number738606-46-7
MW344.5
Purity>98%
FormulaC19H36O5
SMILESCC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
TargetAMPK,ATP Citrate Lyase
SolubilitySoluble in DMSO (up to at least 25 mg/ml)

Bioactivity

−
In Vivo
The mechanism of action of TC-1002 primarily targets two liver enzymes: ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK), inhibiting the synthesis of steroids and fatty acids while promoting the oxidation of mitochondrial long-chain fatty acids. ETC-1002 enhances AMPK phosphorylation levels, reduces the activity of MAPKs, and diminishes the production of pro-inflammatory cytokines and chemokines.
In Vitro
ETC-1002 is an inactivated prodrug that is transformed into its activated form, an ACL inhibitor (activated state, ETC-1002-CoA), through endogenous liver ACS activity in vivo. It inhibits the migration of leukocytes to the peritoneal cavity of mice induced by sulfatide. Additionally, ETC-1002 restores the activity of lipid AMPK and reduces the phosphorylation of JNK in diet-induced obesity mouse models, leading to a decrease in the expression of the macrophage-specific marker 4F/80.
Cell Research
Primary rat hepatocytes and differentiated human MDMs are treated with indicated concentrations of ETC-1002 for 12 h. Working solutions of ETC-1002 are prepared in serum-free RPMI 1640 containing 12 mM HEPES, 10,000 U/ml penicillin, and 100 μg/ml streptomycin. (Only for Reference)

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
ESP 55016; ETC-1002
−
  • ETC-1002

    ETC-1002 [orb1224103]

    >98% (HPLC)

    738606-46-7

    344.4861

    C19H36O5

    5 mg, 10 mg, 25 mg, 100 mg, 50 mg, 2 mg, 500 mg, 1 g

Compound Identifiers

PubChem CID
10472693 ↗

Key Properties

−
No computed properties available.

Protocol Information